Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

Charlton, Michael; Burns, Justin M.; Pedersen, Rachel; Watt, Kymberly D.; Heimbach, Julie K.; Dierkhising, Ross A.

doi:10.1053/j.gastro.2011.06.061

Cited by 1,022 publications

(836 citation statements)

References 24 publications

Supporting

Mentioning

777

Contrasting

Unclassified

Order By: Relevance

“…An RCT for liver transplantation cannot be conducted for ethical reasons. Overall results of reported cohort studies indicated that survival after liver transplantation for NASH patients was approximately the same as for liver transplant patients with other causes of hepatic failure [103][104][105][106][107][108].…”

Section: Metformin Cq: Are Biguanides Effective For Patients With Nafmentioning

confidence: 97%

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in industrialized countries worldwide, and has become a serious public health issue not only in Western countries but also in many Asian countries including Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. In turn, a large proportion of NAFLD/NASH is the liver manifestation of metabolic syndrome, suggesting that NAFLD/NASH plays a key role in the pathogenesis of systemic atherosclerotic diseases. Currently, a definite diagnosis of NASH requires liver biopsy, though various noninvasive measures are under development. The mainstays of prevention and treatment of NAFLD/NASH include dietary restriction and exercise; however, pharmacological approaches are often necessary.Currently, vitamin E and thiazolidinedione derivatives are the most evidence-based therapeutic options, although the clinical evidence for long-term efficacy and safety is limited. This practice guideline for NAFLD/NASH, established by the Japanese Society of Gastroenterology in cooperation with The Japan Society of Hepatology, covers lines of clinical evidence reported internationally in the period starting from 1983 to January 2012, and each clinical question was evaluated using the GRADE system. Based on the primary release of the full version in Japanese, this English summary provides the core essentials of this clinical practice guideline comprising the definition, diagnosis, and current therapeutic recommendations for NAFLD/NASH in Japan.

show abstract

Section: Metformin Cq: Are Biguanides Effective For Patients With Nafmentioning

confidence: 97%

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The 3-and 5-year survival is not different in NAFLD vs no NAFLD; NAFLD carries a higher risk of death from cardiovascular complications and sepsis, whereas the risk of graft failure is lower [145,146]. The overall mortality is associated with BMI and diabetes, with 50% of cases with BMI >35 kg/m 2 dying within 1 year of transplantation [147].…”

Section: Liver Transplantationmentioning

confidence: 99%

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

2016

Diabetologia

551

248

View full text Add to dashboard Cite

“…NAFLD is a relatively newer condition, and although the initial description dates back to 1980,1 its full spectrum and impact as a major chronic liver disease have only been recognized for the past 2 decades 2. Today, NAFLD is a leading indication for liver transplantation in the United States3 and contributes as the underlying etiology to a significant percentage of hepatocellular carcinoma (HCC) cases each year 4…”

mentioning

confidence: 99%

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes

Alkhouri

Poordad

Lawitz

2018

Hepatology Communications

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD is a known risk factor for developing T2D and has a very high prevalence in those with existing T2D. The diabetes spectrum includes several conditions from prediabetes to T2D to insulin‐dependent diabetes leading to macrovascular and microvascular complications. Similarly, NAFLD has a histologic spectrum that ranges from the relatively benign nonalcoholic fatty liver to the aggressive form of nonalcoholic steatohepatitis with or without liver fibrosis to nonalcoholic steatohepatitis‐cirrhosis leading to end‐stage liver disease. The management of T2D has witnessed significant changes over the past few decades with multiple new drug classes entering the treatment algorithm. Unfortunately, there are no U.S. Food and Drug Administration‐approved medications to treat NAFLD, and guidelines for the management of NAFLD are less established. However, the field of drug development in NAFLD has witnessed a revolution over the past 5 years with the establishment of a regulatory pathway for Food and Drug Administration approval; this has generated substantial interest from pharmaceutical companies. Several diabetes medications have been studied as potential treatments for NAFLD with promising results; moreover, drugs that target specific pathways that play a role in NAFLD development and progression are being developed at a rapid pace. Given the similarities between NAFLD and T2D in terms of pathogenesis, underlying risk factors, and disease spectrum, lessons learned from optimizing treatment for T2D can be extrapolated to the management of NAFLD. The aim of this review is to use the founding principles of the comprehensive type 2 diabetes management algorithm to optimize the management of NAFLD. (Hepatology Communications 2018;2:778‐785)

show abstract

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

Cited by 1,022 publications

References 24 publications

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes

Contact Info

Product

Resources

About